Navigation Links
Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
Date:3/13/2008

SOUTH SAN FRANCISCO, Calif., March 13 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer, today announced that it has initiated a Phase 2 study of RAV12, its lead clinical product, in combination with gemcitabine in the treatment of patients with metastatic pancreatic cancer.

The Phase 2 Pancreatic Cancer Study will be conducted at approximately 20 institutions in the US. The first institution to open the trial is the Fox Chase Cancer Center in Philadelphia, PA. Eight sites will participate through the clinical trials consortium, the Pancreatic Cancer Research Team. More information regarding the study can be found at http://www.clinicaltrials.gov.

After an initial dose-escalation run-in segment of approximately 18 patients, the Phase 2 trial will enroll 63 patients in an efficacy segment. The target dose and schedule of RAV12, 0.75 mg/kg twice weekly, was chosen in a recently completed Phase 1/2a trial that involved 53 patients. Final analysis of the Phase 1/2a study will be available the third quarter of 2008.

About RAV12

RAV12 is a novel, chimeric monoclonal antibody that is directed against a primate-specific glycotope (sugar structure) that is widely displayed on the surfaces of tumor cells, particularly those of gastrointestinal origin (gastroesophageal, pancreatic, and colorectal cancers). Preclinical studies have demonstrated that RAV12 may kill tumor cells in a number of ways: first, the antibody is directly cytotoxic to a human colon cancer cell line in vitro through induction of oncotic cell death, a form of cell death characterized by cell and organelle swelling and loss of membrane integrity; second, the antibody mediates antibody-dependent cellular cytotoxicity; third, the antibody mediates complement dependent cell killing; and finally, the antibod
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
2. Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
3. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
4. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
5. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
6. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
7. Inclinix Announces New Patent for Expert System Platform
8. Genzyme Announces Presentation of New Positive Data on Carticel(R)
9. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
10. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... March 3, 2011 Palatin Technologies, Inc. (NYSE Amex: ... Drug Administration (FDA) has cleared Palatin,s request to begin a ... (IND) application using a subcutaneously administered formulation of PL-3994, an ... of asthma. "We are excited about the ...
... 3, 2011 Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... the FDA,s Office of New Drugs ("OND") in Maryland and ... contained in its New Drug Application ("NDA") 22-481 support the ... "We appreciate OND,s consideration of our appeal.  While we ...
Cached Medicine Technology:FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for Asthma 2FDA's Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone 2FDA's Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone 3
(Date:7/10/2014)... the clinical indicators most strongly associated with concussion is ... evidence-based guidelines for concussion diagnosis, prognosis, and treatment, according ... , official journal of the Congress ... Lippincott Williams & Wilkins , a part of ... on analysis of the best available research data, a ...
(Date:7/10/2014)... the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan ... patients a new therapeutic combination to combat resistant sarcomas. ... treatment could stabilize the growth of these tumors have ... of Cancer ., Sarcomas , Sarcomas are a ... several subtypes. It can affect from children to older ...
(Date:7/9/2014)... If you think winning is one of the key determinants ... along with other mental bonuses ranked near the bottom of ... of 11 big fun factors, according to a new study. ... it comes to the "fun" factor, very little research had ... this elusive conceptuntil now. , The results of this study ...
(Date:7/9/2014)... associated with a small increased risk of prostate cancer, ... cancer according to a new study from Harvard School ... association remained even among men who received regular PSA ... be explained by diagnostic bias. It is the largest ... the link between vasectomy and prostate cancer. , The ...
(Date:7/9/2014)... heretofore hidden ways that cells are regulated, scientists at ... cancer cells more likely to metastasize. , What,s more, ... by blocking two other proteins that are normally linked ... processes could have unexpected ties. , The study, ... Nature , points to the possibility of new cancer ...
Breaking Medicine News(10 mins):Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3
... of his work,to ensure that all Pennsylvanians have access ... said 35,000 uninsured,individuals who have been waiting to enroll ... to receive health coverage at a,monthly premium of $33.50., ... and peace of mind,that every Pennsylvanian deserves," said Governor ...
... 40% of patients stopped taking drugs in Italian study , , ... taking cholesterol-lowering statins doubled their risk of dying in the ... an Italian study finds. , A number of other studies ... the study authors noted. , For instance, the Italian study ...
... cord dysfunction (VCD) is the sudden, abnormal narrowing of the ... is characterized by a noise that can mimic the sound ... an asthma attack though it does not respond to asthma ... the disorder using breathing and relaxation techniques to help the ...
... than visually inspecting the disease, doctors have no genetic blueprint ... Tumors generally are ranked by how deeply the growth has ... the skin, the more lethal the cancer, but some patients ... from thin ones. Two melanoma patients with cancers of ...
... Disease Control report that nearly 25 million women are infected with ... more than three million are thought to have one of the ... warts. , HPV is linked to oropharyngeal cancer and may be ... developed to treat HPV might decrease the risk of these cancers, ...
... group suggests , THURSDAY, Aug. 30 (HealthDay News) -- ... suffer oral allergy syndrome (OAS), which results from a ... and trees and similar proteins in some fresh fruits ... known as pollen-food syndrome -- include: itchiness, tingling or ...
Cached Medicine News:Health News:Governor Rendell Offers adultBasic Coverage to 35,000 Uninsured Pennsylvanians 2Health News:Stopping Statins After Stroke Doubles Death Risk 2Health News:Stopping Statins After Stroke Doubles Death Risk 3Health News:Study finds some kids are being misdiagnosed with asthma 2Health News:Gene signature spells poor outcome 2Health News:Human Papilloma Virus vaccines may decrease chances of oral cancer 2Health News:Pollen, Fruits, Veggies Help Trigger Oral Allergy Syndrome 2
The Triage Profiler Shortness of Breath Panel provides rapid risk assessment and differential diagnosis of patients presenting to the emergency department with shortness of breath and risk assessment...
... an affordable path to Sonesta flexibility. ... and back adjustments. Packaged with basic ... line of Sonesta add-ons, allowing you ... your needs; complete Sonesta flexibility at ...
... The Sonesta 6202 is the ... with our most popular accessories, ... for a myriad of exam ... (yet quiet) motors allow fast ...
... The BiliChek measures total serum bilirubin ... no risk of infection compared to the ... Using light, BiliChek tests bilirubin levels without ... Only the replaceable plastic tip touches the ...
Medicine Products: